Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,263 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Successful discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in real-world settings.
Ochiai M, Tanaka E, Sato E, Inoue E, Abe M, Saka K, Sugano E, Sugitani N, Higuchi Y, Yamaguchi R, Sugimoto N, Ikari K, Nakajima A, Yamanaka H, Harigai M. Ochiai M, et al. Among authors: abe m. Mod Rheumatol. 2021 Jul;31(4):790-795. doi: 10.1080/14397595.2021.1883252. Epub 2021 Mar 1. Mod Rheumatol. 2021. PMID: 33538611
Risk of herpes zoster in patients with rheumatoid arthritis in the biologics era from 2011 to 2015 and its association with methotrexate, biologics, and corticosteroids.
Yamaguchi R, Tanaka E, Nakajima A, Inoue E, Abe M, Sugano E, Sugitani N, Saka K, Ochiai M, Higuchi Y, Sugimoto N, Ikari K, Yamanaka H, Harigai M. Yamaguchi R, et al. Among authors: abe m. Mod Rheumatol. 2022 Apr 18;32(3):522-527. doi: 10.1093/mr/roab026. Mod Rheumatol. 2022. PMID: 34897494
Differences in patients' population and efficacy/effectiveness of biologic disease-modifying antirheumatic drugs between randomized controlled trials and real-world settings in patients with rheumatoid arthritis - using the IORRA cohort.
Sugano E, Tanaka E, Inoue E, Sakai R, Abe M, Saka K, Sugitani N, Ochiai M, Yamaguchi R, Higuchi Y, Sugimoto N, Ikari K, Nakajima A, Yamanaka H, Harigai M. Sugano E, et al. Among authors: abe m. Mod Rheumatol. 2022 Jul 1;32(4):675-685. doi: 10.1093/mr/roab067. Mod Rheumatol. 2022. PMID: 34918127 Review.
Changes in treatment adherence and behaviour during the COVID-19 pandemic in Japanese patients with rheumatoid arthritis: Results from cross-sectional study in the IORRA cohort.
Tanaka E, Inoue E, Abe M, Saka K, Sugano E, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M. Tanaka E, et al. Among authors: abe m. Mod Rheumatol. 2022 Oct 15;32(6):1193-1195. doi: 10.1093/mr/roab120. Mod Rheumatol. 2022. PMID: 35445721 Free PMC article. No abstract available.
Evaluation of the Rheumatoid Arthritis Observation of Biologic Therapy risk score in Japanese patients with rheumatoid arthritis starting first biologic disease-modifying antirheumatic drugs: A validation study using the Institute of Rheumatology, Rheumatoid Arthritis cohort data.
Higuchi T, Tanaka E, Inoue E, Abe M, Saka K, Sugano E, Sugitani N, Higuchi Y, Ochiai M, Yamaguchi R, Ikari K, Yamanaka H, Harigai M. Higuchi T, et al. Among authors: abe m. Mod Rheumatol. 2024 Jul 6;34(4):693-699. doi: 10.1093/mr/road066. Mod Rheumatol. 2024. PMID: 37409749
6,263 results